Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I).
Investors 2
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.09.2016 | Series A | $16.88M | - |
| 14.10.2014 | Series A | $11.95M | - |
Mentions in press and media 5
| Date | Title | Description |
| 06.09.2016 | Rigontec extends Series A with additional €15 million | To advance novel RIG-I targeted immuno-oncology therapeutics. The company also announced opening of Cambridge, MA office. |
| 06.09.2016 | Rigontec Raises €15M in Third Closing of Series A Funding | Rigontec, a Bonn, Germany-based developer of RIG-I targeting RNA therapeutics, secured €15m in the third and final closing of its Series A round.
Backers included Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründe... |
| 24.03.2015 | Rigontec Raises €4.8M in Second Closing of Series A Financing | Rigontec GmbH, a Bonn, Germany-based biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, raised €4.8m in a second closing of its Series A financing round.
The investment brought ... |
| 14.10.2014 | Rigontec Raises €9.45M in Series A Financing | Rigontec GmbH, a Bonn, Germany-based biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, raised €9.45m in Series A financing.
The round was co-led by Wellington Partners and Boeh... |
| - | Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics | Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that it has secured EUR 15 million in a third and final closing of its Series A round. The financing represents additional capital from current investors Boehringer I... |
Reviews 0
